E76.29 Other mucopolysaccharidoses

Name of the Condition

• Other mucopolysaccharidoses (ICD-10 Code: E76.29)

Summary

Other mucopolysaccharidoses are a group of rare inherited disorders characterized by the accumulation of glycosaminoglycans (GAGs) due to enzyme deficiencies. These conditions disrupt normal cellular function, leading to progressive multisystem involvement, including skeletal abnormalities, organ enlargement, and neurological impairment. Early recognition and management are important to address complications and slow disease progression.

Causes

The disorders are caused by genetic mutations that impair enzymes responsible for breaking down glycosaminoglycans. These mutations result in the accumulation of undegraded GAGs in cells, tissues, and organs, disrupting normal structure and function. The specific enzyme deficiency determines the type and severity of the condition.

Risk Factors

• Family history of mucopolysaccharidoses or related lysosomal storage disorders.
• Consanguineous relationships (increased risk of recessive inheritance).
• Ethnic or geographic populations with higher carrier rates for specific mutations.

Symptoms

• Skeletal abnormalities, such as short stature, joint stiffness, or dysostosis multiplex.
• Organ enlargement (e.g., hepatosplenomegaly).
• Neurological symptoms, including developmental delay, seizures, or cognitive impairment.
• Coarse facial features.
• Respiratory or cardiac complications.

Diagnosis

Diagnosis involves clinical evaluation, enzyme activity testing, genetic testing, and imaging studies to assess organ involvement. Urine tests may detect elevated GAG levels, while molecular analysis confirms specific mutations. Early diagnosis is critical for initiating timely interventions.

Treatment Options

Treatment focuses on managing symptoms and slowing disease progression. Options may include enzyme replacement therapy, hematopoietic stem cell transplantation, physical therapy, and supportive care for organ dysfunction. Multidisciplinary care addresses multisystem involvement.

Prognosis and Follow-Up

Prognosis varies by subtype and severity, with some forms progressing rapidly and others more slowly. Regular follow-up with specialists (e.g., neurologists, orthopedists) is essential to monitor complications and adjust care plans. Early intervention can improve quality of life.

Complications

Potential complications include severe skeletal deformities, respiratory failure, cardiac disease, vision or hearing loss, and cognitive decline. Untreated, these can lead to significant disability or reduced lifespan.

Lifestyle & Prevention

While prevention is not possible, supportive measures like physical therapy, adaptive equipment, and nutritional support can enhance daily functioning. Genetic counseling is recommended for families with a history of the disorder.

When to Seek Professional Help

Seek medical attention for unexplained developmental delays, skeletal pain, organ enlargement, or neurological symptoms. Prompt evaluation is crucial for early diagnosis and management.

Tips for Medical Coders

Use E76.29 for "Other mucopolysaccharidoses" when the specific subtype is not documented or does not fit narrower codes (e.g., Morquio or Sanfilippo). Ensure documentation supports the diagnosis and excludes more specific codes where applicable.